FDA
-
-
-
-
-
-
-
Allarity to present stenoparib Phase 2 poster at ESMO congress
-
-
-
-
-
-
-
Allarity presents cancer drug data at AACR conference
-
-
-
-
-
-
-
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
-
-
-
-
-
-
-
Allarity reports median survival exceeds 25 months in ovarian cancer trial
-
-
-
-
-
-
-
Allarity Therapeutics (ALLR) Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
-
-
-
-
-
-
-
Allarity Therapeutics (ALLR) Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
-
-
-
-
-
-
-
Allarity Therapeutics, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court fo
-
330,211 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

